The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

Thank you for registering for our on-demand launch webinar

You’ve registered for our on-demand webinar – Launching a Product to the NHS in 2024: How to Deliver True Value

The webinar took place on Wednesday 31 January 2024 and watch the recording below.

Book a free launch excellence clinic with us

Strongly and passionately connected with the NHS, we offer sophisticated advisory, consultancy and customer identification services, and bring together NHS leaders from across systems and sectors to maximise your launch. We are currently offering the opportunity to have a 1-1 launch excellence clinic. These are 1 hour slots where your whole team can come together to discuss any challenges they may be facing. The Wilmington Healthcare Consulting team will be on hand to offer immediate advice and potential solutions. To reserve a spot, please get in touch

Answers to your questions from the webinar

Where do you go for and how do you pull together an ICS analysis to inform those strategy plans? The ABPI health systems navigator is a tool available to all member companies for just this sort of analysis, covering maturity and sophistication, priorities, finance and governance. Deeper and bespoke analysis, system by system, is available from Wilmington Healthcare – please contact us for more information.

You mentioned the ABPI Health Systems Navigator. ABPI is Pharma only – what about medtech? Wilmington Healthcare built the navigator for the ABPI and specialises in detailed health systems data. We can supply this kind of insight to medtech companies – so the answer here is, call us about your challenges and requirements and we can assess your needs and provide you with the solutions you need.

What are the biggest policy barriers and mismatches for launch? It’s not so much policy, which broadly encourages the involvement of industry, but reality which is the problem; of too little staffing, too little resource to properly engage. There are some policies the NHS must follow when implementing new treatment pathways, such as a commitment to net zero, that industry could engage more with – how does your product launch address the green agenda? Addressing access and health inequalities is another such area. NICE TAs can be another policy barrier – even with NICE approval, some funding decisions are make locally, and so create another layer of market access.

In my experiences so far, the prescribing clinician still feels very removed from the multi-dimensional aspects and priorities that the ICS will have. I’ve yet to hear a prescriber make a multi-dimensional prescribing decision. So how do we help the prescriber to engage with those other aspects? We talk of a multi-dimensional VP encompassing system, organisation, service, clinician and patient. Clinicians have their own priorities and the point is to adapt the multi-dimensional proposition to include meaningful engagement for them. However remember they will also it is all about patients; access for patients, healthcare equity for patients, faster treatment for patients, a smooth and effective evidence based pathway for patients, a better experience for patients, more independence and self-management for patients, more positive outcomes for patients. Place these aspects centrally in your value proposition. Some clinicians may sit on PCN boards or ICBs or be part of a larger network which must consider system and organisational needs. Data and visualisation tools can help here – Wilmington Healthcare specialises in these to help set out the case for change to clinicians and other decision-makers – and make it something they can easily demonstrate the value to other internal stakeholders.

 

Our Knowledge Hub contains an extensive repository of free-to-access white papers, videos, articles and other resources exploring the changing NHS landscape and its impact on Industry.

To receive content directly to your inbox, sign up for our newsletter.

You can also follow us on LinkedIn and Twitter.